B-Raf IN 17
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAFWT, VEGFR-2, and FGFR-1 in A375 cell line, with IC50 values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer[1].
Product Specifications
UNSPSC
12352005
Target
FGFR; Raf; VEGFR
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/b-raf-in-17.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C2NC(C3=CC=CC=C3)=NC2=C1)N/N=C4C(NC5=C/4C=C(C=C5)Br)=O
Molecular Formula
C22H14BrN5O2
Molecular Weight
460.28
References & Citations
[1]Allam RM, et al. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma. Bioorg Chem. 2024 Feb 26;146:107243.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
EXTRAClean Cell Culture Media Exosome Purification and RNA Isolation Maxi Kit
Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), CF647 conjugate, 0.1mg/mL
Claudin 10 (CLDN10) (NM_006984) Human Over-expression Lysate
